AlphAIalphai — Financial news for AI agents
BenzingaOCT 162 min read$WHWK

Whitehawk Therapeutics Stock Is Trading Higher Thursday: What's Going On? - Whitehawk Therapeutics (NASDAQ:WHWK)

Whitehawk Therapeutics, Inc. ( NASDAQ:WHWK ) shares are rising Thursday after the company announced a multi-year collaboration with Tempus AI Inc ( NASDAQ:TEM ) to support the development of its oncology pipeline. WHWK stock is racing ahead of the pack. Check the market position here.

Original reporting
Benzinga · Dylan Berman
Published Oct 16, 2025, 3:52 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Oct 16, 2025, 4:30 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Whitehawk Therapeutics Stock Is Trading Higher Thursday: What's Going On? - Whitehawk Therapeutics (NASDAQ:WHWK) — source image
Source · www.benzinga.com
Decision brief

The 30-second read

$WHWKBullishMed
01

Why it matters

This strategic partnership is expected to bolster WHWK's development efforts, potentially leading to future revenue streams.

02

Market read

The news is highly relevant for investors in biotech and oncology sectors, especially those holding or considering WHWK.

03

What to watch

Potential overvaluation due to hype; broader market corrections could negate gains.

Timing: Immediate, as the news is recent and stock prices are reacting.

Background

Whitehawk Therapeutics announced a multi-year collaboration with Tempus AI Inc., aiming to advance its oncology pipeline.

Company-level read

Ticker impact

$WHWKBullishHigh confidence
Context

High relevance due to recent collaboration announcement and stock movement.

Expected impact

Moderate upward movement expected in the short to medium term.

Evidence & confidence

The collaboration signifies strategic advancement and potential revenue growth, which are typically bullish signals. The stock's recent rally supports this outlook.

$TEMNeutralMedium confidence
Context

Moderate relevance as the collaboration involves Tempus AI Inc., but the direct impact on TEM's stock is limited.

Expected impact

Limited or negligible impact on TEM's stock price.

Evidence & confidence

While the partnership is beneficial for TEM, it does not directly alter TEM's financial outlook significantly at this stage.

Market effects

Sector

Potential positive sentiment in biotech and pharmaceutical sectors, especially companies involved in oncology.

Regional

Limited to US markets with possible ripple effects in biotech indices.

Global

Minimal; primarily relevant to US-based biotech stocks.

Counterpoint

What could challenge this read

The rally may be short-lived if the collaboration does not lead to tangible clinical or financial milestones.

Key entities

  • Company
    Whitehawk Therapeutics

    A biotech firm focused on oncology therapeutics.

  • Company
    Tempus AI Inc.

    A technology company specializing in AI-driven healthcare solutions.

Read at source← All news

Related articles

AUG 27
$TEMMedAI 9/10

Tempus AI (TEM) Jumped on Moderna’s Melanoma Win. Did its $1.5B Personalis Acquisition Just Get Validated?

Tempus AI (TEM) shares rose after Moderna and Merck reported positive Phase 3 trial results for a personalized cancer therapy, validating Personalis' sequencing technology. Tempus agreed to acquire Personalis for $1.5B, with the deal pending. Personalis' technology is distinct from the main target of the acquisition, NeXT Personal, a tumor-informed molecular residual disease test. Tempus reported 9,000 MRD tests in Q2, while Personalis generated $22.357M in revenue and delivered 10,384 clinical

insidermonkey.com3 min
AUG 24
$TEMMedAI 8/10

Tempus Receives FDA Clearance for its AI Product Intended to Detect Signs of Pulmonary Hypertension From Standard ECGs

Tempus AI, Inc. (NASDAQ: TEM) received FDA clearance for its AI product, Tempus ECG-PH, designed to detect signs of pulmonary hypertension from standard ECGs. This is the third FDA-cleared cardiovascular device in Tempus' portfolio, aiming to help clinicians identify at-risk patients earlier. The product analyzes ECG data but is not intended for standalone diagnosis.

biospace.com2 min
AUG 23
$TEMHighAI 8/10

Why Tempus AI Skyrocketed This Week

Tempus AI (TEM) shares rose 39.5% this week after Merck and Moderna reported positive Phase 3 trial data for their cancer vaccine, which uses technology from Personalis, a company Tempus is acquiring. Tempus's market cap is $13B, and its stock is still down about 10% over the past year. The acquisition is expected to close late 2024 or early 2027.

fool.com2 min
AUG 22
$PSNLHighAI 8/10

Personalis Stock Jumps As Tempus AI Acquisition Reshapes Outlook

Personalis Inc. (PSNL) stock rose 9.41% after reporting Q2 revenue of $22.4M, exceeding consensus estimates. The company agreed to be acquired by Tempus AI for $16.25 per share. Clinical volume for its NeXT Personal MRD test surged 199% year over year, with guidance for over 500% clinical revenue growth in 2026. Management will halt guidance and earnings calls as the company pivots to a merger-driven setup.

stockstotrade.com3 min